

## CONTENTS

## ORAL PRESENTATIONS

Simonida Bobic	
<b>S1 – Adjuvant chemotherapy in HR+ breast cancer, to give it or to omit? . . . . .</b>	<b>3</b>
Tajana Silovski	
<b>S2 – Who is the candidate for adjuvant treatment with CDK4/6 inhibitor and what CDK4/6 inhibitor to choose? . . . . .</b>	<b>4</b>
Feđa Đorđević	
<b>S3 – Perioperative therapy of esophageal cancer – are the standards changing? . . . . .</b>	<b>5</b>
Nikola Peulić, Nikola Milašević	
<b>S4 – Long-term treatment in patient with squamous cell esophageal carcinoma . . . . .</b>	<b>6</b>
Nevenka Lukovac-Janjić	
<b>S5 – Therapeutic approach in the treatment of locally advanced cervical cancer at the KCCG Institute of Oncology (M interlace) . . . . .</b>	<b>6</b>
Urška Janžič	
<b>S6 – Screening for lung cancer in the region . . . . .</b>	<b>7</b>
Katja Mohorčič	
<b>S7 – Immunotherapy in resectable non-small-cell lung cancer . . . . .</b>	<b>8</b>
Jelena Spasić	
<b>S8 – Immunotherapy in small cell lung cancer . . . . .</b>	<b>10</b>

## POSTER PRESENTATIONS

Ana Geltar, Urška Janžič	
<b>P1 – Treatment patterns and outcomes of EGFR positive NSCLC patients treated with osimertinib in first line setting . . . . .</b>	<b>15</b>
Dora Antunović, Marin Šunjić, Kristina Urch, Jure Murgić, Nina Dabelić, Jasmina Marić Brozić	
<b>P2 – Clinical outcomes of melanoma brain metastases in the era of immunotherapy and targeted therapy: a retrospective single center study . . . . .</b>	<b>16</b>
Andrijana Kojić, Feđa Đorđević, Katarina Ljujić, Dimitrije Kolović, Jelena Spasić	
<b>P3 – Toxicity of brigatinib in the treatment of metastatic ALK-positive non-small cell lung cancer – a case report . . . . .</b>	<b>17</b>

Dimitrije Đurđević, Slobodan Kutić, Sofija Pantelić, Dušan Ristić, Branka Živković	
<b>P4 – Use of the temozolomide and irinotecan (TEMIRI) chemotherapy protocol in the treatment of relapsed / refractory ewing sarcoma in adults: a single-center experience .</b>	18
Ana Paric, Maja Pezer Naletilic, Kresimir Tomic, Monika Glibic, Sanda Cale, Ana Puljic Cuk, Semir Vranic	
<b>P5 – Prognostic significance of the KELIM score as a predictor of response to chemotherapy in patients with epithelial ovarian cancer . . . . .</b>	19
Irena Conić, Slavica Stojnev, Ivan Petković, Ana Cvetanović, Dane Krtinić	
<b>P6 – Activity of pembrolizumab in cervical cancer – case report . . . . .</b>	20
Emir Sokolović, Amina Hadžibeganović, Ema Čampara, Amil Družić, Elma Kapisazović, Timur Cerić, Berisa Hasanbegović, Semir Bešlija	
<b>P7 – Epithelioid hemangioendothelioma in Bosnia and Herzegovina: a case series analysis of different treatment strategies in an ultra-rare cancer . . . . .</b>	21
Ivana Vukovic, Bojana Golubovic, Nada Cicmil Sarić	
<b>P8 – Epithelioid hemangioendothelioma in Bosnia and Herzegovina: a case series analysis of different treatment strategies in an ultra-rare cancer . . . . .</b>	22
Ivana Vukovic, Sanja Lekic, Bojana Scekcic, Bojana Golubovic	
<b>P9 – Descriptive analysis: characteristics of patients with high-grade ovarian cancer on maintenance olaparib therapy with bevacizumab in Montenegro vs the PAOLA-1 study . . . . .</b>	23
Ivo Todorčić, Luka Trkmić, Tomislav Tokić, Marija Križić, Katarina Čular, Natalija Dedić Plavetić, Marko Granić, Tajana Silovski	
<b>P10 – Development of medication related osteonecrosis of the jaw in patients with HR-positive HER2-negative metastatic breast cancer treated with cycle-dependent kinase 4/6 inhibitors and antiresorptive therapy . . . . .</b>	25
Ivo Dilber, Ivan Zekanović, Mirisa Tokić, Katarina Horvat Pavlov, Kata Međugorac	
<b>P11 – Aplastic anemia caused by chemoimmunotherapy in patient with lung cancer: a case report. . . . .</b>	26
Jovana Trifunović, Nemanja Trifunović, Sara Filipović, Nemanja Stevanović, Miroslav Kreačić	
<b>P12 – Rare but real: treating metastatic mammary-like adenocarcinoma of the vulva as triple-negative breast cancer. . . . .</b>	27
Josip Basić, Ivan Romić, Hrvoje Silovski	
<b>P13 – Liver transplantation in a patient with hepatocellular carcinoma and chronic hepatitis C: the role of downstaging with immunotherapy. . . . .</b>	28
Katarina Ljujić, Feđa Đorđević, Dimitrije Kolović, Andrijana Kojić, Nemanja Stanić, Neda Nikolić, Jelena Spasić	
<b>P14 – Real-world data of pembrolizumab monotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC) – experience from the Institute for Oncology and Radiology of Serbia (IORS). . . . .</b>	30

Katarina Čular, Kristina Kanceljak, Marija Križić, Marina Popović, Natalija Dedić Plavetić, Tajana Silovski	
<b>P15 – Clinical characteristics and outcomes of short-term responders to CDK4/6 inhibitors in HR+/HER2– mBC . . . . .</b>	<b>31</b>
Laura Barta, Hrvoje Blažević, Klaudia Babić, Filip Jakov Klisović, Tomislav Bubalo, Roko Bjelica, Sven Bival, Marija Križić, Marko Granić, Tajana Silovski	
<b>P16 – Characteristics of patients with medication-related osteonecrosis of the jaw induced by antiresorptive therapy . . . . .</b>	<b>32</b>
Kristina Kanceljak, Katarina Čular, Ana Kelečić, Martina Matec, Marija Križić, Marina Popović, Natalija Dedić Plavetić, Tajana Silovski	
<b>P17 – Impact of CKD4/6 inhibitors switch in HR+/HER2– metastatic breast cancer treatment: a single-center experience . . . . .</b>	<b>33</b>
Lazar Popović, Maja Popović, Stela Novak, Ivana Kolarov-Bjelobrk, Bojana Vranjković, Stefan Đurić, Teodora Urošević, Nemanja Maletin, Gorana Matovina-Brko	
<b>P18 – First experience with antibody-drug conjugates trastuzumab deruxtecan and sacituzumab-govitecan in heavily pretreated patients with metastatic breast cancer . . . . .</b>	<b>34</b>
Lazar Popović, Ana Cvetanović	
<b>P19 – Correlation between adjuvant chemotherapy treatment decision in HR+/HER2– early breast cancer before and after mammaprint test: two-center experience report . . . . .</b>	<b>35</b>
Lea Burilo, Ivan Romić, Hrvoje Silovski	
<b>P20 – Suspected IPMN-B in patient with PSC/AIH overlap syndrome . . . . .</b>	<b>36</b>
Lazar Popović, Maja Popović, Stefan Đurić, Nemanja Maletin, Teodora Urošević, Stela Novak, Gorana Matovina-Brko	
<b>P21 – Immunotherapy maintenance versus immunotherapy after progression on platinum-based chemotherapy in the treatment of locally advanced or metastatic urothelial cancer . . . . .</b>	<b>37</b>
Lea Toula, Marko Lovrić, Zrna Antunac Golubić, Iva Nikles, Šime Bušelić, Ivan Vičić, Milena Gnjidić, Marija Gamulin	
<b>P22 – Adjuvant pembrolizumab for clear-cell renal cell carcinoma – a single centre experience. . . . .</b>	<b>39</b>
Lidija Pavlović, Andjela Karaferic, Milana Matovic, Simonida Bobic, Slobodan Kutić, Jovana Mijucic, Teodora Novakovic, Marijana Milović-Kovačević	
<b>P23 – Olaparib maintenance therapy in BRCA 1/2-mutated ovarian cancer patients with renal insufficiency: a single-institution experience . . . . .</b>	<b>40</b>
Mirjana Pavlović Mavić, Petra Jakšić, Petra Sertić, Ljubica Vazdar, Robert Šeparović, Ana Tečić Vuger	
<b>P24 – Treatment patterns in elderly patients with metastatic colorectal cancer during COVID-19 pandemics . . . . .</b>	<b>41</b>

Mirta Peček, Sanja Langer, Milica Vrbančić, Petra Jakšić, Ljiljana Mayer, Ljubica Vazdar, Robert Šeparović	
<b>P25 – Correlation between nutritional status evaluated by nutritional screening tools and laboratory nutrition assessments in patients with metastatic colon cancer . . . . .</b>	<b>42</b>
Maja Popović, Gorana Matovina-Brko, Dragana Petrović, Stefan Đurić, Lazar Popović	
<b>P26 – Prognostic factors of overall survival and progression free survival in Hodgkin lymphoma patients . . . . .</b>	<b>43</b>
Maja Popović, Gorana Matovina-Brko, Dragana Petrović, Stefan Đurić, Lazar Popović	
<b>P27 – Positron emission tomography after two cycles of chemotherapy in the treatment of Hodgkin’s lymphoma . . . . .</b>	<b>44</b>
Maja Popović, Nemanja Maletin, Gorana Matovina-Brko, Stefan Đurić, Stela Novak, Teodora Urošević, Svetlana Salma, Lazar Popović	
<b>P28 – Second line treatment of clear cell renal cell carcinoma after progression on a tyrosine kinase inhibitor . . . . .</b>	<b>45</b>
Marija Živković Radojević, Katarina Janković, Aljoša Mandić, Miloš Grujić, Katarina Krasić, Vladimir Grbić, Nevena Folić, Marko Folić, Ksenija Bošnjaković, Aleksandra Marković, Dragan Lončar, Neda Milosavljević	
<b>P29 – International analysis of the level of knowledge about human papillomavirus infections in the population of young athletes in a volleyball camp. . . . .</b>	<b>47</b>
Marko Marjanović, Jelena Radić, Nemanja Petrović, Aleksandar Đurić, Stela Novak, Nikola Anđelić, Bojana Damjanović	
<b>P30 – Synchronous occurrence of hepatocellular carcinoma and lung adenocarcinoma: a favorable response to combined systemic therapy with atezolizumab and bevacizumab – a case report. . . . .</b>	<b>48</b>
Nikola Milašević, Nevenka Lukovac-Janjić, Dijana Bošković, Nikola Peulić	
<b>P31 – Treatment of BRAF mutant melanoma with BRAFi/MEKi combination therapy in clinical practice in Montenegro. . . . .</b>	<b>50</b>
Nevenka Lukovac-Janjić, Ivana Vukovic, Dragana Ognjenovic Nikcevic, Bojana Golubovic	
<b>P32 – Case report: pulmonary hypertension as the first manifestation of malignant disease. . . . .</b>	<b>51</b>
Nikola Milašević, Nada Cicmil Sarić, Nevenka Lukovac-Janjić, Dijana Bošković	
<b>P33 – Efficacy of pembrolizumab in clinical practice for metastatic melanoma in Montenegro . . . . .</b>	<b>52</b>
Sanja Lekic, Milan Sorat, Bojana Golubovic, Ivana Vukovic	
<b>P34 – Efficacy and safety of ribociclib in patients with HR+/HER2 advanced breast cancer – clinical practice in Montenegro . . . . .</b>	<b>53</b>
Sanja Lekic, Milan Sorat, Ivana Vukovic, Bojana Golubovic	
<b>P35 – Efficacy and safety of palbociclib in patients with HR+/HER2 advanced breast cancer – clinical practice in Montenegro . . . . .</b>	<b>54</b>

Sanja Lekic, Ivana Vukovic, Bojana Golubovic, Milica Radisavljevic <b>P36 – Herena: real-world experience with adjuvant chemotherapy and HER2 blockade after upfront surgery for stage II and III HER2 – positive breast cancer . . . . .</b>	56
Sanja Lekic, Ivana Vukovic, Bojana Golubovic, Milica Radisavljevic <b>P37 – Herena: real-world treatment patterns of early HER2+ breast cancer in Montenegro . . . . .</b>	57
Sanja Lekic, Ivana Vukovic, Bojana Scekcic <b>P38 – Case report: myoepithelial tumor of the nasopharynx. . . . .</b>	58
Sanja Lekic, Ana Popovic, Milica Bojic, Tanja Nenezic <b>P39 – Prurigo nodularis induced by anti-HER2 therapy: a rare but challenging skin reaction in breast cancer management . . . . .</b>	59
Sara Filipović, Jovana Trifunović, Perica Jockić, Nemanja Trifunović, Miroslav Kreačić, Nebojša Mitrović <b>P40 – Massive hemoperitoneum as the initial presentation of metastatic testicular germ cell tumor: a case report . . . . .</b>	60
Stefan Đurić, Maja Popović, Dragana Petrović, Gorana Matovina-Brko, Teodora Urošević, Nemanja Maletin, Stela Novak, Lazar Popović <b>P41 – Comparison between treatment outcomes among patients with diffuse-large B-cell lymphoma treated between 2003-2010 and 2017-2021 treated with rituximab-based immunochemotherapy . . . . .</b>	61
Šime Bušelić, Marija Gamulin, Milena Gnjidić, Zrna Antunac Golubić, Borislav Belev, Iva Nikles, Ana Koši Kunac, Lea Toula, Marko Lovrić <b>P42 – Adjuvant pembrolizumab for renal cell carcinoma: one – year experience at University Hospital Centre Zagreb . . . . .</b>	62
Luka Balog, Lovro Balen, Katarina Čular, Natalija Dedić Plavetić, Tajana Silovski <b>P43 – Monitoring of estradiol values in premenopausal woman receiving ovarian function suppression in combination with anastrozole and abemaciclib for HR positive HER2 negative early breast cancer treatment. . . . .</b>	63
Viktor Šabarić, Kata Međugorac, Krešimir Blažičević, Luka Simetić, Slaven Stanojlović, Gordana Horvatić Herceg, Davorin Herceg <b>P44 – Immune-related adverse events in metastatic melanoma patients treated with combination immunotherapy . . . . .</b>	64
Lovro Balen, Luka Balog, Marija Križić, Katarina Čular, Martina Matec, Natalija Dedić Plavetić, Marina Popović, Tajana Silovski <b>P45 – Characteristics of patients with high-risk HR-positive, HER2-negative early breast cancer treated with adjuvant abemaciclib: a single-centre experience . . . . .</b>	65
<b>AUTHOR INDEX . . . . .</b>	67